$DICE News

Last published 3y ago

3y agoDICE LLYLilly Completes Acquisition of DICE TherapeuticsPR NewswireINDIANAPOLIS, Aug. 9, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the successful completion of its acquisition of DICE Therapeutics, Inc. (NASDAQ:DICE). The acquisition expands Lilly's
3y agoDICE LLYLilly Announces Extension of Tender Offer to Acquire DICEPR NewswireINDIANAPOLIS, July 25, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) today announced the extension of the expiration of the tender offer to acquire all of the issued and outstanding shares ("Shares") of
3y agoDICE EMAN NETI PDCEMoore Kuehn Encourages EMAN, NETI, PDCE, DICE, and NETI Investors to Contact Law FirmPR NewswireNEW YORK, July 9, 2023 /PRNewswire/ -- Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims concerning whether the following
3y agoDICE EMAN NETI PDCEMoore Kuehn Encourages DICE, PDCE, EMAN, and NETI Investors to Contact Law FirmGlobeNewswireNEW YORK, July 06, 2023 (GLOBE NEWSWIRE) -- Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims concerning whether the
3y agoDICE NETI NEX SURFMoore Kuehn Encourages SURF, NEX, NETI, and DICE Investors to Contact Law FirmPR NewswireNEW YORK, June 20, 2023 /PRNewswire/ -- Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims concerning whether the following
3y agoGS CAR CVX XOM+8Stocks making the biggest moves midday: Goldman Sachs, Avis, Rivian, Nike and moreCNBCThese are the stocks posting the largest moves in midday trading.
3y agoLLY DICEEli Lilly to acquire Dice Therapeutics for $2.4 billion in autoimmune treatment pushCNBCDice is a biopharmaceutical company that uses a proprietary technology platform to develop new oral therapeutic drugs for autoimmune diseases.
3y agoBABA undefined DICE LLY+4Stocks making the biggest premarket moves: Alibaba, Dice Therapeutics, Avis and moreCNBCThese are the stocks posting the largest moves in the premarket.
3y agoDICE LLYLilly to Acquire DICE Therapeutics to Advance Innovation in ImmunologyPR NewswireINDIANAPOLIS and SOUTH SAN FRANCISCO, Calif., June 20, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) and DICE Therapeutics, Inc. (NASDAQ:DICE) today announced a definitive agreement for Lilly to acquire
3y agoDICEDICE Therapeutics to Host R&D Investor Event on Tuesday, June 20, 2023GlobeNewswireSOUTH SAN FRANCISCO, Calif., June 13, 2023 (GLOBE NEWSWIRE) -- DICE Therapeutics, Inc. (NASDAQ:DICE) (DICE or the Company), a biopharmaceutical company leveraging its proprietary DELSCAPE technology platform to build a
3y agoDICEDICE Therapeutics Reports First Quarter 2023 Financial Results and Recent HighlightsGlobeNewswireFirst patient dosed in global Phase 2b clinical trial of lead oral IL-17 inhibitor, DC-806, in moderate-to-severe psoriasisTopline data from Phase 1 clinical trial of second oral IL-17 inhibitor, DC-853, in healthy
3y agoDICEDICE Therapeutics to Participate in the Bank of America Securities 2023 Healthcare ConferenceGlobeNewswireSOUTH SAN FRANCISCO, Calif., May 03, 2023 (GLOBE NEWSWIRE) -- DICE Therapeutics, Inc. (NASDAQ:DICE) (DICE or the Company), a biopharmaceutical company leveraging its proprietary DELSCAPE technology platform to build a
3y agoDICEDICE Therapeutics to Participate in the H.C. Wainwright Autoimmune & Inflammatory Disease Virtual ConferenceGlobeNewswireSOUTH SAN FRANCISCO, Calif., March 23, 2023 (GLOBE NEWSWIRE) -- DICE Therapeutics, Inc. (NASDAQ:DICE) (DICE or the Company), a biopharmaceutical company leveraging its proprietary DELSCAPE technology platform to build
3y agoDICEDICE Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent HighlightsGlobeNewswireIND application for DICE's lead oral IL-17 antagonist, DC-806, cleared by FDA; global Phase 2b clinical trial in patients with moderate-to-severe psoriasis on track to initiate in 1H 2023First participants dosed in Phase
3y agoDICEDICE Therapeutics Announces Late-Breaking Presentation at the 2023 American Academy of Dermatology (AAD) Annual MeetingGlobeNewswireSOUTH SAN FRANCISCO, Calif., March 01, 2023 (GLOBE NEWSWIRE) -- DICE Therapeutics, Inc. (NASDAQ:DICE), a biopharmaceutical company leveraging its proprietary technology platform to build a pipeline of novel oral
3y agoDICEDICE Therapeutics to Participate at Upcoming Investor ConferencesGlobeNewswireSOUTH SAN FRANCISCO, Calif., Feb. 08, 2023 (GLOBE NEWSWIRE) -- DICE Therapeutics, Inc. (NASDAQ:DICE), a biopharmaceutical company leveraging its proprietary technology platform to build a pipeline of novel oral
3y agoDICEDICE Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare ConferenceGlobeNewswireSOUTH SAN FRANCISCO, Calif., Jan. 04, 2023 (GLOBE NEWSWIRE) -- DICE Therapeutics, Inc. (NASDAQ:DICE), a biopharmaceutical company leveraging its proprietary technology platform to build a pipeline of novel oral
4y agoDICEDICE Therapeutics Reports Third Quarter 2022 Financial Results and Recent HighlightsGlobeNewswireReported positive Phase 1 proof-of-concept data supporting the further development of lead oral IL-17 antagonist, DC-806, as potential best-in-class oral agent for psoriasisDemonstrated direct inhibition of a cytokine
4y agoDICEDICE Therapeutics to Present at Upcoming Investor ConferencesGlobeNewswireSOUTH SAN FRANCISCO, Calif., Nov. 03, 2022 (GLOBE NEWSWIRE) -- DICE Therapeutics, Inc. (NASDAQ:DICE), a biopharmaceutical company leveraging its proprietary technology platform to build a pipeline of novel oral
4y agoDICEDICE Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional SharesGlobeNewswireSOUTH SAN FRANCISCO, Calif., Oct. 17, 2022 (GLOBE NEWSWIRE) -- DICE Therapeutics, Inc. (NASDAQ:DICE), a biopharmaceutical company leveraging its proprietary technology platform to build a pipeline of novel oral
4y agoDICEDICE Announces Pricing of Upsized Public Offering of Common StockGlobeNewswireSOUTH SAN FRANCISCO, Calif., Oct. 12, 2022 (GLOBE NEWSWIRE) -- DICE Therapeutics, Inc. (NASDAQ:DICE), a biopharmaceutical company leveraging its proprietary technology platform to build a pipeline of novel oral
4y agoDICEDICE Announces Proposed Public Offering of Common StockGlobeNewswireSOUTH SAN FRANCISCO, Calif., Oct. 11, 2022 (GLOBE NEWSWIRE) -- DICE Therapeutics, Inc. (NASDAQ:DICE), a biopharmaceutical company leveraging its proprietary technology platform to build a pipeline of novel oral
4y agoDICEDICE Therapeutics Announces Positive Topline Data from Phase 1 Clinical Trial of Lead Oral IL-17 Antagonist, DC-806, for PsoriasisGlobeNewswireClinical proof-of-concept in psoriasis patients achieved with a mean percentage reduction in PASI from baseline at 4 weeks of 43.7% in the high dose group compared to 13.3% in the placebo group, with an exploratory
4y agoDICEDICE Therapeutics Reports Second Quarter 2022 Financial Results and Recent HighlightsGlobeNewswireCompleted enrollment in Phase 1 clinical trial of lead oral IL-17 antagonist DC-806; topline proof-of-concept data in healthy volunteers and psoriasis patients expected in 2H 2022 SOUTH SAN FRANCISCO, Calif., Aug. 11, 2022 (GLOBE NEWSWIRE) -- DI
4y agoDICEDICE Therapeutics Announces Completion of Enrollment in Phase 1 Clinical Trial of Lead Oral IL-17 Antagonist, DC-806, for the Treatment of PsoriasisGlobeNewswireTopline proof-of-concept data in healthy volunteers and psoriasis patients expected in 2H 2022 SOUTH SAN FRANCISCO, Calif., July 21, 2022 (GLOBE NEWSWIRE) -- DICE Therapeutics, Inc. (NASDAQ:DICE), a biopharmaceutical company leveraging its proprie
4y agoDICEDICE Therapeutics to Present at the 2022 Jefferies Healthcare ConferenceGlobeNewswireSOUTH SAN FRANCISCO, Calif., June 01, 2022 (GLOBE NEWSWIRE) -- DICE Therapeutics, Inc. (NASDAQ:DICE), a biopharmaceutical company leveraging its proprietary technology platform to build a pipeline of novel oral therapeutic candidates to treat chronic d
4y agoDICEDICE Therapeutics Reports First Quarter 2022 Financial Results and Recent HighlightsGlobeNewswireTopline proof-of-concept data from Phase 1 clinical trial of oral IL-17 antagonist DC-806 in healthy volunteers and psoriasis patients expected in mid-2022 Current cash provides runway through mid-2024 and multiple expected key clinical milestones
4y agoDICEDICE Therapeutics to Present at the BofA Securities 2022 Healthcare ConferenceGlobeNewswireSOUTH SAN FRANCISCO, Calif., May 03, 2022 (GLOBE NEWSWIRE) -- DICE Therapeutics, Inc. (NASDAQ:DICE), a biopharmaceutical company leveraging its proprietary technology platform to build a pipeline of novel oral therapeutic candidates to treat chronic di
4y agoCBIO DICE VALNShouTi Appoints Sharon Tetlow to Board of DirectorsBusiness WireShouTi Inc., a clinical-stage global biopharmaceutical company developing novel oral therapeutics to treat a wide range of chronic diseases, today announced the appointment of Sharon Tetlow to the company's board of directors. Ms. Tetlow will also serve
4y agoDICEDICE Therapeutics Expands Management Team and Board of DirectorsGlobeNewswireMary Riley, J.D., appointed as general counsel Lisa Bowers, MHSA, and Mittie Doyle, M.D., FACR, join board of directors SOUTH SAN FRANCISCO, Calif., March 28, 2022 (GLOBE NEWSWIRE) -- DICE Therapeutics, Inc. (NASDAQ:DICE), a biopharmaceutical co
4y agoDICEDICE Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Recent HighlightsGlobeNewswireOn track to deliver topline proof-of-concept data from Phase 1 clinical trial of oral IL-17 antagonist DC-806 in healthy volunteers and psoriasis patients in mid-2022 Named development candidate DC-853 from the novel scaffold program 1 series of oral I
4y agoDICEDICE Therapeutics to Present at the 11th Annual SVB Leerink Global Healthcare ConferenceGlobeNewswireSOUTH SAN FRANCISCO, Calif., Feb. 10, 2022 (GLOBE NEWSWIRE) -- DICE Therapeutics, Inc. (NASDAQ:DICE), a biopharmaceutical company leveraging its proprietary technology platform to build a pipeline of novel oral therapeutic candidates to treat chronic d
4y agoDICEDICE Therapeutics to Present at November Investor ConferencesGlobeNewswireSOUTH SAN FRANCISCO, Calif., Nov. 16, 2021 (GLOBE NEWSWIRE) -- DICE Therapeutics, Inc. (NASDAQ:DICE), a biopharmaceutical company leveraging its proprietary technology platform to build a pipeline of novel oral therapeutic candidates to treat chronic d
5y agoDICEDICE Therapeutics Reports Third Quarter 2021 Financial Results and Recent HighlightsGlobeNewswireDosed first healthy volunteers in Phase 1 clinical trial of oral IL-17 antagonist S011806 Successfully completed $234.6 million upsized initial public offering SOUTH SAN FRANCISCO, Calif., Nov. 12, 2021 (GLOBE NEWSWIRE) -- DICE Therapeutics, Inc.
5y agoDICEDICE Therapeutics Initiates Phase 1 Clinical Trial of S011806 for the Treatment of PsoriasisGlobeNewswireSOUTH SAN FRANCISCO, Calif., Oct. 25, 2021 (GLOBE NEWSWIRE) -- DICE Therapeutics, Inc. (NASDAQ:DICE), a biopharmaceutical company leveraging its proprietary technology platform to build a pipeline of novel oral therapeutic candidates to treat chronic d
5y agoDICEDICE Therapeutics Announces Pricing of Upsized Initial Public OfferingGlobeNewswireSOUTH SAN FRANCISCO, Calif., Sept. 14, 2021 (GLOBE NEWSWIRE) -- DICE Therapeutics, Inc. (NASDAQ:DICE), a biopharmaceutical company leveraging its proprietary technology platform to build a pipeline of novel oral therapeutic candidates to treat chronic